Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 224

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 224
---
 event we terminate the agreement at any
time with immediate effect (other than pursuant to the preceding paragraph), we will pay to Dr. Parker all fees which are due to him for
the following 12 months.

Dr. Parker may resign from
his positions at any time if the Company (i) is guilty of any gross negligence which affects him or any dishonesty towards or concerning
him or (ii) becomes insolvent, makes any composition or enters into any deed of arrangement with its creditors or the equivalent. If Dr.
Parker resigns due to these reasons, we will pay to Dr. Parker all fees which are due to him for the following 12 months. Further, in
the event that Dr. Parker is unable, due to an accident, illness or injury, to undertake his duties for the Company in accordance with
the terms of the Appointment Agreement for a period of more than six consecutive months, he may resign at any time without any
rights to damages or compensation. Dr. Parker is also required to resign in connection with the Board of Directors determination that
his acceptance of any other employment, engagement, appointment, interest or involvement with any business or person competes or conflicts
with his appointment and would result in a serious conflict of interest or Dr. Parker reasonably determines such interest would result
in a serious conflict of interest, and Dr. Parker accepts such employment, engagement, appointment, interest or involvement, without any
rights to damages or compensation. If Dr. Parker resigns for any other reason, he must provide 12 months written notice.

Compensation of Senior Management

The following table summarizes
the compensation earned by our senior management during 2024 (including for any service on any our subsidiaries), including one former
executive officer.

| Name                                              |     | Salary 
 (£)    |         |     | Bonus  
 (£)(1) |   |     | Option        
 Awards (£)(2) |         |     | All Other    
 Compensation 
 (3)(£)       |        |     | Total 
 (£)   |         |
| Stephen Stamp                                     |     |        |         |     |        |   |     |               |         |     |              |        |     |       |         |
| Chief Executive Officer & Chief Financial Officer |     |        | 249,991 |     |        | - |     |               | 157,808 |     |              |  3,025 |     |       | 410,824 |
| Dmitry Zamory